Company Overview

AbCellera Biologics Inc. is a biotechnology company focused on the discovery and development of antibody-based medicines. The company operates at the intersection of biotechnology, artificial intelligence–enabled drug discovery, and biopharmaceutical research, providing an integrated platform that identifies and optimizes therapeutic antibodies for a wide range of diseases. AbCellera’s primary revenue is generated through research fees, milestone payments, and royalties derived from partnerships with pharmaceutical and biotechnology companies.

The company is uniquely positioned through its end-to-end antibody discovery platform, which combines microfluidics, single-cell analysis, high-throughput screening, and machine learning to rapidly identify antibodies from natural immune repertoires. AbCellera was founded in 2012 and gained global prominence during the COVID-19 pandemic through its role in discovering antibodies used in therapeutic programs, most notably those partnered with Eli Lilly. Since its inception, the company has evolved from a research-focused startup into a publicly traded platform company supporting dozens of active drug discovery programs across multiple therapeutic areas.

Business Operations

AbCellera operates as a single integrated business centered on its antibody discovery and development platform, rather than through traditional product-based divisions. The company collaborates with biopharmaceutical partners to discover antibodies, after which partners typically assume responsibility for clinical development, regulatory approval, and commercialization. AbCellera generates revenue through upfront research payments, downstream development and regulatory milestones, and potential long-term royalties on approved therapies.

Operations are supported by proprietary technologies including microfluidic systems capable of screening millions of immune cells, computational biology tools, and large-scale wet-lab infrastructure. AbCellera conducts research primarily in-house while maintaining partnerships with global pharmaceutical companies and academic institutions. The company also advances select internal programs into preclinical and early clinical development to retain greater economic participation. Its core operating subsidiary is AbCellera Biologics Inc., with additional wholly owned entities supporting research and international operations.

Strategic Position & Investments

AbCellera’s strategic direction emphasizes expanding the scale and scope of its antibody discovery engine while increasing participation in downstream value creation. Growth initiatives include investing in new screening modalities, expanding machine learning capabilities, and broadening the range of therapeutic targets and disease areas addressed by its platform. The company has also invested in internal drug programs to capture higher long-term returns compared to purely partnered discovery efforts.

Strategically, AbCellera has pursued selective acquisitions and equity investments to enhance its technology stack and capabilities, though acquisitions have been limited and targeted rather than transformative. The company maintains a broad and diversified partner portfolio, reducing reliance on any single program or counterparty. Emerging areas of focus include multispecific antibodies, immune-mediated diseases, and oncology, supported by continued investment in automation and data-driven discovery workflows.

Geographic Footprint

AbCellera is headquartered in Canada, with its principal offices and research facilities located in Vancouver, British Columbia. The company’s operations are primarily concentrated in North America, where it conducts the majority of its laboratory research and platform development activities.

Despite its centralized physical footprint, AbCellera has a significant global presence through partnerships and collaborations with biopharmaceutical companies in North America, Europe, and Asia-Pacific. These international relationships enable the company to participate in drug development programs targeting global markets, even where it does not maintain substantial physical infrastructure.

Leadership & Governance

AbCellera was founded by scientists with expertise in immunology and bioengineering, and its leadership continues to emphasize a science-driven, platform-centric strategy. Governance is structured around a board of directors with experience in biotechnology, pharmaceuticals, and capital markets, supporting long-term investment in research and technology.

Key members of the executive leadership team include:

• Carl Hansen – Chief Executive Officer
• Jonathan Shapiro – Chief Financial Officer
• Emma Sheldon – Chief Technology Officer
• Jason Amsen – Chief Scientific Officer
• Jamie McCutcheon – Chief Business Officer

The leadership team promotes a long-term vision centered on building durable discovery infrastructure, fostering deep scientific partnerships, and translating biological data into scalable therapeutic innovation.